| 25228534 |
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
Okuno, Y,
Iafrate, AJ,
Friboulet, L,
Koike, S,
Shaw, AT,
Engelman, JA,
Khan, TM,
Lockerman, EL,
Takeuchi, K,
Taiji, M,
Fujita, N,
Gainor, JF,
Katayama, R
|
Clin Cancer Res |
2014 |
| 18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Zozulya, S,
George, RE,
Gilliland, DG,
Morris, SW,
Luther, W,
London, WB,
Hanna, M,
Meyerson, M,
McGrady, P,
Sanda, T,
Gregor, VE,
Look, AT,
Zhang, J,
Fröhling, S,
Ahn, Y,
Diller, L,
Webb, TR,
Zhou, W,
Greulich, H,
Gray, NS,
Xue, L
|
Nature |
2008 |
| 27009859 |
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
Gokhale, V,
Groysman, MJ,
Pongtornpipat, P,
Wang, M,
Tapia, EO,
Rajan, SS,
Amin, AD,
Schatz, JH,
Li, L
|
Oncotarget |
2016 |
| 24419060 |
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice
Soga, T,
Kondoh, Y,
Furutani, T,
Shindou, N,
Konagai, S,
Ueno, Y,
Sakagami, H,
Kuromitsu, S,
Mori, M,
Kudoh, M,
Saito, R,
Doihara, H,
Shimada, I,
Fushiki, H,
Mori, K
|
Mol Cancer Ther |
2014 |
